News
Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 9, 2020Research Study to Use Data and Samples from NurOwn® Phase 3 Clinical Trial
The ALS Association and I AM ALS announced today that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics (NASDAQ: BCLI), a biotechnology company, to...
-
Jun 3, 2020Management to Host One-on-One Partnering Meetings
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Dr. Ralph Kern, M.D, President and Chief Medical...
-
Jun 2, 2020The fully enrolled placebo-controlled Phase 3 trial is evaluating NurOwn® investigational treatment in ALS patients
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today an update on the Company's Phase 3 pivotal trial...
-
May 27, 2020Experience Developing, Seeking Regulatory Approval of and Commercializing Multi-Billion Dollar Neurology Therapies
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that Stacy R. Lindborg, Ph.D. has been appointed...
-
May 7, 2020BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate UpdateConference Call and Webcast Today at 8:30 a.m. Eastern Time
NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial...
Tools
Investors
- Overview
- News
- Events & Presentations
- Stock Information
- Financial Reports & Filings
- Corporate Governance